borderline diabetes

GLP-1 Less Frequent Dosing May Maintain Weight Loss

by

TOPLINE: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) administered at off-label reduced dosing maintained weight-loss benefits, with patients retaining the effects even with 2-4 weeks between doses. METHODOLOGY: GLP-1 RAs are transforming obesity treatment, but high costs and shortages limit patient access. Clinicians have suggested a less frequent dosing to maintain weight loss, but evidence … Read more

Empagliflozin as First-Line Therapy Reduces Weight, BMI, and Waist Circumference in Prediabetes and Diabetes

by

Archyde Empagliflozin and Weight Loss: A Promising First-Line Treatment for Diabetes and Prediabetes Table of Contents 1. Empagliflozin and Weight Loss: A Promising First-Line Treatment for Diabetes and Prediabetes 2. Understanding the Study 3. Key Findings 4. What This Means for patients 5. Limitations and Future Directions 6. Conclusion 7. How Does Empagliflozin Contribute to … Read more